Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow J L, Keidar S
Lipid Research Laboratory, Technion Faculty of Medicine, Rappaport Institute for Research in the Medical Sciences, Haifa, Israel.
Cardiovasc Res. 1999 Dec;44(3):579-87. doi: 10.1016/s0008-6363(99)00239-4.
To investigate the possible mechanisms of the antiatherosclerotic effects of the angiotensin-converting enzyme (ACE) inhibitor, fosinopril, in apolipoprotein (apo) E deficient mice.
Apo E deficient (E0) mice at the age of 8 weeks received either placebo or a high dose (25 mg/kg/d) of fosinopril supplemented in their drinking water.
After 12 weeks of treatment, fosinopril reduced the aortic lesion size by 70%, compared with the placebo group. At this dosage, fosinopril significantly reduced blood pressure from 93 +/- 2 mmHg before treatment to 70 +/- 2 mmHg at the end of the treatment period (P < 0.005). Fosinopril also increased the resistance of the mice plasma low density lipoprotein (LDL) to CuSO4-induced oxidation, as shown by a 90% reduction in the LDL content of malondialdehyde (MDA) and also by a prolongation of the lag time required for the initiation of LDL oxidation (from 100 min in the placebo-treated mice to more than 240 min in the fosinopril-treated mice; P < 0.001). In addition, fosinopril inhibited CuSO4-induced oxidation of LDL that was obtained from the aortas of the treated mice, as shown by an 18% and 37% reduction in the LDL content of lipid peroxides and hydroperoxy-cholesterol linoleate, respectively, compared with the placebo-treated mice (P < 0.01). A low dosage of fosinopril (5 mg/kg/d) that was still adequate to reduce their plasma ACE activity and LDL propensity to lipid peroxidation was insufficient to lower their blood pressure. This dosage also reduced the aortic lesion size in the apo E deficient mice by 40% (P < 0.01).
The antiatherogenic effects of fosinopril in apo E deficient mice are due not only to blood pressure reduction but also to the direct inhibition of angiotensin II-dependent effects, which are probably also associated with the inhibition of LDL oxidation.
研究血管紧张素转换酶(ACE)抑制剂福辛普利在载脂蛋白(apo)E缺陷小鼠中抗动脉粥样硬化作用的可能机制。
8周龄的apo E缺陷(E0)小鼠饮用补充了安慰剂或高剂量(25mg/kg/d)福辛普利的水。
治疗12周后,与安慰剂组相比,福辛普利使主动脉病变大小减少了70%。在此剂量下,福辛普利使血压从治疗前的93±2mmHg显著降至治疗期末的70±2mmHg(P<0.005)。福辛普利还增加了小鼠血浆低密度脂蛋白(LDL)对硫酸铜诱导氧化的抵抗力,表现为LDL中丙二醛(MDA)含量降低90%,以及LDL氧化起始所需的延迟时间延长(从安慰剂处理小鼠的100分钟延长至福辛普利处理小鼠的超过240分钟;P<0.001)。此外,与安慰剂处理小鼠相比,福辛普利抑制了从处理小鼠主动脉中获得的LDL的硫酸铜诱导氧化,表现为脂质过氧化物和氢过氧化胆固醇亚油酸酯的LDL含量分别降低了18%和37%(P<0.01)。低剂量的福辛普利(5mg/kg/d)虽然仍足以降低其血浆ACE活性和LDL脂质过氧化倾向,但不足以降低其血压。该剂量也使apo E缺陷小鼠的主动脉病变大小减少了40%(P<0.01)。
福辛普利在apo E缺陷小鼠中的抗动脉粥样硬化作用不仅归因于血压降低,还归因于对血管紧张素II依赖性作用的直接抑制,这可能也与LDL氧化的抑制有关。